Загрузка...
Management of myelodysplastic syndromes after failure of response to hypomethylating agents
Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic syndrome (MDS). However, only around 50% of patients respond to these agents, and responses tend to be transient, with loss of response frequently happening within 2 years and being associated with very poor pro...
Сохранить в:
| Опубликовано в: : | Ther Adv Hematol |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6515843/ https://ncbi.nlm.nih.gov/pubmed/31156799 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620719847059 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|